1. What is a thrombus?

According to WHO reports, in the past 30 years, the death caused by thrombosis has always accounted for more than 45% of the total death toll, far exceeding cancer and infectious diseases. Thrombosis is the common pathogenesis of stroke and ischemic heart disease, the top two fatal cardiovascular diseases in the country. The incidence of stroke in China is generally twice that of the United States, and the annual death rate is about 2 million.

The pathological process of thrombotic diseases involves three major systems: vascular endothelium, coagulation and fibrinolysis. It has been confirmed that in the prethrombotic state, the vascular endothelium, coagulation and fibrinolysis systems have been changed. TAT, PIC, TM, t-PAIC, FDP and D-Dimer are effective responses to the early changes of the body's vascular endothelium, coagulation and fibrinolysis systems. effective indicator. It is suitable for early diagnosis and risk assessment of high-risk groups of thrombosis in various clinical departments.

2. Clinical significance

3. Application scenarios

The six combined applications of new thrombus are helpful for the early diagnosis, treatment and monitoring of DIC: early indication of postoperative thrombosis; monitoring of the effect of anticoagulant therapy and thrombolytic therapy: diagnosis, prevention and treatment of malignant tumor coagulation monitoring.

The six new thrombus items in China are completely dependent on imported raw materials, which are expensive, long delivery time and poor specificity. Ai Weidi Bio has actively invested in research and development, independently developed and launched the first six new thrombus items (TAT, PIC, TM, t-PAIC, FDP) , D-Dimer) diagnostic raw materials and reagents in large packages, the performance is comparable to that of internationally renowned brands.

4. Product Information

Free samples of six diagnostic materials for AIVD's new thrombus! First come, first served, while stocks last. Welcome to inquire!